This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Does Zymeworks Inc. (ZYME) Have the Potential to Rally 42.84% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 42.8% in Zymeworks Inc. (ZYME). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Predict a 64.61% Upside in Zymeworks Inc. (ZYME): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 64.6% upside potential for Zymeworks Inc. (ZYME). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zymeworks Inc. (ZYME) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -49.02% and 45.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals (ANIP) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of 100% and 20.41%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Cytek Biosciences, Inc. (CTKB) Q2 Earnings Lag Estimates
by Zacks Equity Research
Cytek Biosciences, Inc. (CTKB) delivered earnings and revenue surprises of -66.67% and 6.83%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arbutus (ABUS) delivered earnings and revenue surprises of 16.67% and 7.39%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
New Strong Buy Stocks for July 26th
by Zacks Equity Research
ANGI, SFIX, ZVIA, ZYME and HOWL have been added to the Zacks Rank #1 (Strong Buy) List on July 26, 2023.
Caribou Biosciences, Inc. (CRBU) Surges 45.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Caribou Biosciences, Inc. (CRBU) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 42.19% and 307.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Regeneron (REGN) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Regeneron (REGN) delivered earnings and revenue surprises of 9.08% and 8.12%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Zymeworks Inc. (ZYME) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zymeworks Inc. (ZYME) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Zymeworks Inc. (ZYME) closed at $9.41 in the latest trading session, marking a +0.11% move from the prior day.
Zymeworks Inc. (ZYME) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Zymeworks Inc. (ZYME) closed the most recent trading day at $8.20, moving +0.12% from the previous trading session.
Zymeworks Inc. (ZYME) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Zymeworks Inc. (ZYME) closed at $8.63 in the latest trading session, marking a +1.89% move from the prior day.
Zymeworks Inc. (ZYME) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 0.65% and 8.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Inc. (ZYME) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Zymeworks Inc. (ZYME) closed at $8.22, marking a -1.91% move from the previous day.
Travere Therapeutics (TVTX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Travere (TVTX) delivered earnings and revenue surprises of 0.96% and 1.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Inc. (ZYME) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
Zymeworks Inc. (ZYME) closed the most recent trading day at $8.57, making no change from the previous trading session.
Zymeworks Inc. (ZYME) to Report Q4 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zymeworks Inc. (ZYME) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Zymeworks Inc. (ZYME) closed the most recent trading day at $8.90, moving -0.22% from the previous trading session.
Can Zymeworks (ZYME) Beat Expectations This Earnings Season?
by Zacks Equity Research
In the absence of a marketed product, Zymeworks (ZYME) is expected to provide an update on its pipeline candidates, mainly zanidatamab for the treatment of patients with HER2-expressing cancers, at the fourth-quarter conference call.
Zymeworks Inc. (ZYME) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Zymeworks Inc. (ZYME) closed the most recent trading day at $9.70, moving -1.22% from the previous trading session.
Strength Seen in CRISPR Therapeutics AG (CRSP): Can Its 7.2% Jump Turn into More Strength?
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Zymeworks Inc. (ZYME) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Zymeworks Inc. (ZYME) closed at $9.45 in the latest trading session, marking a -0.94% move from the prior day.